Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Frequently asked questions
What sector does Nanosonics Limited (NNCSF) operate in?
Nanosonics Limited belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is Nanosonics Limited (NNCSF) current stock price?
As of the latest data, Nanosonics Limited stock price is $1.84, with a previous close of $1.84.
What is Nanosonics Limited (NNCSF) current market capitalization?
Nanosonics Limited market cap is approximately 550.47 million.
What is Nanosonics Limited (NNCSF) Earnings Per Share (EPS)?
The trailing EPS is $0.04.
What is Nanosonics Limited (NNCSF) Price-to-Earnings (P/E) ratio?
Nanosonics Limited current P/E ratio is 46.
What is Nanosonics Limited (NNCSF) EBITDA?
Nanosonics Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 10.87 million.
Does Nanosonics Limited (NNCSF) pay dividends?
No. Nanosonics Limited does not pay a dividend.
What is Nanosonics Limited (NNCSF) beta (volatility) score?
Nanosonics Limited has a beta of 1.146, meaning its volatility is roughly in line with the market.
